Biologics in pediatric psoriasis – efficacy and safety

References

• Hanseler T, Christopher E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol. 1985;13:450–456.
   PubMed Web of Science ®Google Scholar
• Dogra S, Kaur I. Childhood psoriasis. Indian J Dermatol, Venereol Leprol. 2010;76:357–365.
   PubMed Web of Science ®Google Scholar
• Chiam LY, De Jager ME, Giam YC, et al. Juvenile psoriasis in European and Asian children: similarities and differences. Br J Dermatol. 2011;164:1101–1103.
   PubMed Web of Science ®Google Scholar
• Augustin M, Glaeske G, Radtke M, et al. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol. 2010;162:633–636.
   PubMed Web of Science ®Google Scholar
• Dogra S, Kumar B. Epidemiology of skin diseases in school children: a study from northern India. Paed Dermatol. 2003;20:470–473.
   PubMed Web of Science ®Google Scholar
• Kumar B, Jain R, Sandhu K, et al. Epidemiology of childhood psoriasis: a study of 419 patients from northern India. Int J Dermatol. 2004;43:654–658.
   PubMed Web of Science ®Google Scholar
• Bryld LE, Sorensen TI, Andersen KK, et al. High body mass index in adolescent girls precedes psoriasis hospitalization. Acta Derm Venereol. 2010;90:488–493.
   PubMed Web of Science ®Google Scholar
• Smith CH, Anstey AV, Barker JN, et al. British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009. Br J Dermatol. 2009;161:987–1019.
   PubMed Web of Science ®Google Scholar
• Ohtsuki M, Terui T, Ozawa A, et al. Biologics Review Committee of the Japanese Dermatological Association. Japanese guidance for use of biologics for psoriasis. J Dermatol. 2013;40:683–695.
   PubMed Web of Science ®Google Scholar
• Van Geel MJ, Oostveen AM, Hoppenreijs EP, et al. Methotrexate in pediatric plaque-type psoriasis: long-term daily clinical practice results from the Child-CAPTURE registry. J Dermatol Treat. 2015;20:1–7.
   Google Scholar
• Di Lernia V, Stingeni L, Boccaletti V, et al. Effectiveness and safety of cyclosporine in pediatric plaque psoriasis: a multicentric retrospective analysis. J Dermatolog Treat. 2015;10:1–4.
   Google Scholar
• Dogra S, Mahajan R, Narang T, et al. Systemic cyclosporine treatment in severe childhood psoriasis: a retrospective chart review. J Dermatolog Treat. 2017 Feb;28(1):18–20.
   PubMed Web of Science ®Google Scholar
• Smith CH, Jabbar-Lopez ZK, Yiu ZZ. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. Br J Dermatol. 2017;177:628–636.
   PubMed Web of Science ®Google Scholar
• Paller AS, Siegfried EC, Langley RG, et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med. 2008;358:241–251.
   PubMed Web of Science ®Google Scholar
• Papp K, Thaci D, Marcoux D, et al. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial. Lancet. 2017;390:40–49.
   PubMed Web of Science ®Google Scholar
• Landells I, Marano C, Hsu MC, et al. Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. J Am Acad Dermatol. 2015;73:594–603.
   PubMed Web of Science ®Google Scholar
• Sanclemente G, Murphy R, Contreras J, et al. Anti-TNF agents for paediatric psoriasis. Cochrane Database Syst Rev. 2015;(11). Art. No.: CD010017. DOI:10.1002/14651858.CD010017.pub2
   PubMed Web of Science ®Google Scholar
• Klufas DM, Wald JM, Strober BE. Treatment of moderate to severe pediatric psoriasis: a retrospective case series. Pediatr Dermatol. 2016;33:142–149.
   PubMed Web of Science ®Google Scholar
• Garber C, Creighton-Smith M, Sorensen EP, et al. Systemic treatment of recalcitrant pediatric psoriasis: a case series and literature review. J Drugs Dermatol. 2015;14:881–886.
   PubMed Web of Science ®Google Scholar
• Saikaly SK, Mattes M. Biologics and Pediatric Generalized Pustular Psoriasis: An Emerging Therapeutic Trend. Muacevic A, Adler JR, eds. Cureus. 2016;8(6):e652. doi:10.7759/cureus.652.
   Google Scholar
• Paller AS, Siegfried EC, Eichenfield LF, et al. Long-term etanercept in pediatric patients with plaque psoriasis. J Am Acad Dermatol. 2010;63:762–768.
   PubMed Web of Science ®Google Scholar
• Paller AS, Eichenfield LF, Langley RG, et al. Subgroup analyses of etanercept in pediatric patients with psoriasis. J Am Acad Dermatol. 2010;63:e38–e41.
   PubMed Web of Science ®Google Scholar
• Langley RG, Paller AS, Hebert AA, et al. Patient-reported outcomes in pediatric patients with psoriasis undergoing etanercept treatment: 12-week results from a phase III randomized controlled trial. J Am Acad Dermatol. 2011;64:64–70.
   PubMed Web of Science ®Google Scholar
• Fraga NA, Paim Mde F, Follador I. Refractory erythrodermic psoriasis in a child with an excellent outcome by using etanercept. An Bras Dermatpl. 2011;86:s144–S147.
   PubMed Web of Science ®Google Scholar
• Napolitano M, Megna M, Balato A. Systemic treatment of pediatric psoriasis: a review. Dermatol Ther. 2016;6:125–142.
   PubMed Web of Science ®Google Scholar
• Baldassano RN. Infliximab in pediatric Crohn’s disease patients. Gastroenterol Hepatol. 2006;2:467.
   PubMedGoogle Scholar
• Tsang V, Dvorakova V, Enright F, et al. Successful use of infliximab as first line treatment for severe childhood generalized pustular psoriasis. J Eur Acad Dermatol Venereol. 2016;30:e117–e119.
   PubMed Web of Science ®Google Scholar
• Skrabl-Baumgartner A, Weger W, Salmhofer W, et al. Childhood generalized pustular psoriasis: longtime remission with combined infliximab and methotrexate treatment. Pediatr Dermatol. 2015;32:e13–e14.
   PubMed Web of Science ®Google Scholar
• Watabe D, Endoh K, Maeda F, et al. Childhood-onset psoriatic onycho-pachydermo-periostitis treated successfully with infliximab. Eur J Dermatol. 2015;25:506–508.
   PubMed Web of Science ®Google Scholar
• Brown G, Wang E, Leon A, et al. Tumor necrosis factor-α inhibitor-induced psoriasis: systematic review of clinical features, histopathological findings, and management experience. J Am Acad Dermatol. 2017;76:334–341.
   PubMed Web of Science ®Google Scholar
• Sherlock ME, Walters T, Tabbers MM, et al. Infliximab-induced psoriasis and psoriasiform skin lesions in pediatric Crohn disease and a potential association with IL-23 receptor polymorphisms. J Pediatr Gastroenterol Nutr. 2013;56:512–518.
   PubMed Web of Science ®Google Scholar
• Fortina AB, Bardazzi F, Berti S. Treatment of severe psoriasis in children: recommendations of an Italian expert group. Eur J Pediatr. 2017 Aug 23;176:1339–1354.
   PubMed Web of Science ®Google Scholar
• Pescitelli L, Dini V, Gisondi P, et al. Erythrodermic psoriasis treated with ustekinumab: an Italian multicenter retrospective analysis. J Dermatol Sci. 2015;78:149–151.
   PubMed Web of Science ®Google Scholar
• Bronckers IMGJ, Seyger MMB, West DP, et al. Safety of systemic agents for the treatment of pediatric psoriasis. JAMA Dermatol. 2017. Published online Sep 13. DOI:10.1001/jamadermatol.2017.3029
   PubMed Web of Science ®Google Scholar
• Reich K, Mrowietz U, Radtke MA, et al. Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest. Arch Dermatol Res. 2015;307:875–883.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Kalb RE, Langley RG, et al. Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies. J Drugs Dermatol. 2014;13:1441–1448.
   PubMed Web of Science ®Google Scholar
• Campanati A, Ganzetti G, Giuliodori K, et al. Biologic therapy in psoriasis: safety profile. Curr Drug Saf. 2016;11:4–11.
   PubMed Web of Science ®Google Scholar
• Pereira R, Lago P, Faria R, et al. Safety of anti-TNF therapies in immune-mediated inflammatory diseases: focus on infections and malignancy. Drug Dev Res. 2015;76:419–427.
   PubMed Web of Science ®Google Scholar
• Patel S, Patel T, Kerdel FA. The risk of malignancy or progression of existing malignancy in patients with psoriasis treated with biologics: case report and review of the literature. Int J Dermatol. 2016;55:487–493.
   PubMed Web of Science ®Google Scholar
• Windschall D, Horneff G. Safety and efficacy of etanercept and adalimumab in children aged 2 to 4 years with juvenile idiopathic arthritis. Clin Rheumatol. 2016;35:2925.
   PubMed Web of Science ®Google Scholar
• Horneff G. Safety of biologic therapies for the treatment of juvenile idiopathic arthritis. Expert Opin Drug Saf. 2015;14:1111–1126.
   PubMed Web of Science ®Google Scholar
• Tarkiainen M, Tynjälä P, Vähäsalo P, et al. Occurrence of adverse events in patients with JIA receiving biologic agents: long-term follow-up in a real-life setting. Rheumatology (Oxford). 2015;54:1170–1176.
   PubMed Web of Science ®Google Scholar
• Burness CB, McKeage K. Adalimumab: a review in chronic plaque psoriasis. Drugs. 2015;75:2119.
   PubMed Web of Science ®Google Scholar
• Leonardi C, Papp K, Strober B. The long-term safety of adalimumab treatment in moderate to severe psoriasis: a comprehensive analysis of all adalimumab exposure in all clinical trials. Am J Clin Dermatol. 2011;12:321–337.
   PubMed Web of Science ®Google Scholar
• Burmester GR, Panaccione R, Gordon KB, et al. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn’s disease. Ann Rheum Dis. 2013;72:517–524.
   PubMed Web of Science ®Google Scholar
• Menter A, Thaci D, Papp KA. Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis. J Am Acad Dermatol. 2015;73(3):410–9 (e6).
   Web of Science ®Google Scholar
• Eickstaedt JB, Killpack L, Tung J, et al. Psoriasis and psoriasiform eruptions in pediatric patients with inflammatory bowel disease treated with anti-tumor necrosis factor alpha agents. Pediatr Dermatol. 2017 May;34(3):253–260.
   PubMed Web of Science ®Google Scholar
• Toussirot É, Aubin F. Paradoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview. RMD Open. 2016;2(2):e000239.
   PubMed Web of Science ®Google Scholar
• Wine-Lee L, Keller SC, Wilck MB, et al. From the Medical Board of the National Psoriasis Foundation: vaccination in adult patients on systemic therapy for psoriasis. J Am Acad Dermatol. 2013;69:1003–1013.
   PubMed Web of Science ®Google Scholar